Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms TROP-2/CD3 bispecific antibodies (Arbele) |
Target |
Action modulators, stimulants, inhibitors |
Mechanism CD3 modulators(T cell surface glycoprotein CD3 modulators), CD3 stimulants(T cell surface glycoprotein CD3 stimulants), Trop-2 inhibitors(Tumor-associated calcium signal transducer 2 inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization ![]() |
Active Organization ![]() |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Gastrointestinal Neoplasms | Preclinical | Hong Kong | ![]() | 22 Mar 2024 |
Colorectal Cancer | Preclinical | China | ![]() | - |
Pancreatic Cancer | Preclinical | China | ![]() | - |
Stomach Cancer | Preclinical | China | ![]() | - |